Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
durvalumab + oleclumab + paclitaxel
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of durvalumab (anti-PD-L1 monoclonal antibody), oleclumab (anti-CD73 monoclonal antibody), and paclitaxel (chemotherapeutic agent). This regimen combines immune checkpoint inhibition, adenosine pathway modulation, and cytotoxic chemotherapy to potentially enhance anti-tumor immune responses and directly kill cancer cells.
- Brand names
- Imfinzi
02
Targets
NT5E (Cluster of Differentiation 73)CD274 (Programmed cell death protein 1 ligand 1)Microtubule
Beyond the preview
Go deeper on durvalumab + oleclumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on durvalumab + oleclumab + paclitaxel.